Improving organ transplant success by promoting immune tolerance
Advancing Transplantation Tolerance in Nonhuman Primates
This study is looking for ways to help organ transplant patients keep their new organs for a long time without needing to take strong medications that weaken their immune system, by finding new treatments that help the body accept the transplant better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11063820 on NIH RePORTER |
What this research studies
This research focuses on enhancing the long-term success of organ transplants by developing methods to induce immune tolerance, which would reduce the need for lifelong immunosuppression. The team will investigate new therapies that target specific immune pathways, particularly the CD40-CD154 interaction, to promote acceptance of transplanted organs. They will also explore innovative nanotechnology to block harmful immune responses and assess the role of memory T cells in preventing tolerance. By understanding these mechanisms, the research aims to create a more favorable immune environment for transplant patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are undergoing or have undergone organ transplantation and are at risk of developing complications due to immune rejection.
Not a fit: Patients who have not received an organ transplant or those with conditions that preclude transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved long-term outcomes for organ transplant recipients, reducing complications such as diabetes, heart disease, and infections.
How similar studies have performed: Previous research has shown promise in targeting immune pathways for transplant tolerance, indicating that this approach may lead to significant advancements in the field.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Adams, Andrew B — University of Minnesota
- Study coordinator: Adams, Andrew B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.